Searching for Solutions

The minutes of the November 19, 2024, FDA joint advisory committee meeting have been posted. As previously reported, this meeting was called to discuss reevaluation of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) and possible changes to minimize burden on patients, pharmacies, and prescribers while maintaining safe use of clozapine.

Our Mission As the philanthropic arm of AAPP, our mission is to advance the psychiatric pharmacy profession by supporting research, scholarship, and practitioner development. The Foundation’s mission complements that of our affiliated association, the American Association of Psychiatric Pharmacists (AAPP), which focuses on serving psychiatric pharmacists and aspiring psychiatric pharmacists and advancing their reach and practice.

Combatting Stigma with Education and Research Mental Health First Aid Training

With your help, the AAPP Foundation can improve access to effective and compassionate care for individuals living with mental illness. This will be accomplished through our initiatives including research, scholarship, and practitioner development of psychiatric pharmacists.

The Journal of the American College of Clinical Pharmacy (JACCP), is creating a themed issue titled “Breaking the Cycle: Advancing Substance Use Disorder Prevention, Treatment, and Recovery”. Submissions (due 7/15/25) may focus on clinical, economic, social, implementation, or other forms of outcomes; innovative team-based care models; and other opportunities to advance the care and treatment of patients with substance use disorders.

Membership in AAPP brings numerous benefits as listed below. This member toolkit provides you a convenient location to explore information and benefits associated with a AAPP membership.

For patients with psychiatric and neurologic illness, there are many barriers to accessing optimal care, including (to name a few) lack of information, limited financial resources, inadequate transportation, and stigma.  The American Association of Psychiatric Pharmacists (AAPP) Foundation envisions a world where individuals with mental health disorders receive optimal care because psychiatric pharmacists are an essential member of the health care team.

How quickly a year comes and goes! It’s hard to believe that it’s been nearly a full 12 months since I assumed the role as your President. As I prepare to hand off the reins to Incoming President Michelle Geier on July 1st and reflect back on the year, it’s fun to think about what has been accomplished. The AAPP Board of Directors has been busy and has engaged in activities that are likely to impact AAPP’s trajectory into the future.

Improving mental health equity is a daunting topic to consider. Diversity, Equity, and Inclusion (DEI) work involves acknowledging the current state as being unacceptable. And being such a vast issue, one can feel at a loss as to what can be done to improve it. When seeking concrete, actionable steps for improving equity in your community, the essential word is “community”.

To improve your experience and support new learning strategies, AAPP is launching a new learning platform later this year. AAPP.org is expected to be offline for the transition December 1-11, 2023. While most of the web site experience will remain familiar, key enhancements will be made.

Thanks to our partnership with Current Psychiatry (CP) published through Quadrant Healthcom Inc., another Savvy Psychopharmacology article was featured in the January 2020 edition of Current Psychiatry. The goal of this section is to present an evidence-based discussion to guide safe, effective prescribing of psychotropic medications. Eva Studer, MD, Tawny L. Smith, PharmD, BCPP, and Smitha Murthy, MD, authored this article on Valproic acid-induced hyperammonemic encephalopathy.